These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33229874)

  • 1. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
    Pall G
    Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy combinations in advanced nonsmall cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2021 Jan; 33(1):73-79. PubMed ID: 33186185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant immunotherapy for melanoma.
    Lee AY; Brady MS
    J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
    Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
    Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
    Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
    Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
    Gentzler RD; Riley DO; Martin LW
    Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer].
    Svatoň M; Blažek J; Burešová M; Vodička J
    Vnitr Lek; 2022; 68(4):217-220. PubMed ID: 36220418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 18. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
    Soria JC; Mauguen A; Reck M; Sandler AB; Saijo N; Johnson DH; Burcoveanu D; Fukuoka M; Besse B; Pignon JP;
    Ann Oncol; 2013 Jan; 24(1):20-30. PubMed ID: 23180113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.